Gammagard S/D Alternatives Compared
| Gammagard S/D (immune globulin intravenous) | Nplate (romiplostim) | Promacta (eltrombopag) |
|
|---|
| Gammagard S/D (immune globulin intravenous) | Nplate (romiplostim) | Promacta (eltrombopag) |
|
|||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Prescription only
Prescribed for Chronic Lymphocytic Leukemia, Primary Immunodeficiency Syndrome, Immune Thrombocytopenia, Kawasaki Disease. Gammagard S/D may also be used for purposes not listed in this medication guide. View more |
Prescription only
Nplate may be used to increase platelet counts above 50 x 109/L in adults and children with ITP who have not had a good response to corticosteroids, immunoglobulins, or removal of their... View more |
Prescription only
Promacta is an oral tablet or suspension that is taken daily to boost platelet numbers in people with chronic ITP, severe aplastic anemia, or chronic hepatitis C. Nausea, diarrhea, infections, and... View more |
Related suggestions Immune Thrombocytopenia
|
|||||||||||||||||||||||
| More about (immune globulin intravenous) | More about Nplate (romiplostim) | More about Promacta (eltrombopag) | ||||||||||||||||||||||||
| Ratings & Reviews | ||||||||||||||||||||||||||
|
Gammagard S/D has an average rating of 7.0 out of 10 from a total of 2 ratings on Drugs.com. 50% of reviewers reported a positive effect, while 0% reported a negative effect. |
Nplate has an average rating of 7.5 out of 10 from a total of 11 ratings on Drugs.com. 73% of reviewers reported a positive effect, while 9% reported a negative effect. |
Promacta has an average rating of 6.8 out of 10 from a total of 18 ratings on Drugs.com. 56% of reviewers reported a positive effect, while 22% reported a negative effect. |
||||||||||||||||||||||||
| Side Effects Experienced by Users Side effects are reported in Drugs.com user reviews and not clinically verified. | ||||||||||||||||||||||||||
|
View all Gammagard S/D side effects |
View all Nplate side effects |
View all Promacta side effects |
||||||||||||||||||||||||
| Drug Class | ||||||||||||||||||||||||||
| Generic Availability | ||||||||||||||||||||||||||
|
N/A |
N/A |
|||||||||||||||||||||||||
| Pricing and Coupons * Prices are without insurance | ||||||||||||||||||||||||||
View all Gammagard S/D prices |
View all Nplate prices |
View all Promacta prices |
||||||||||||||||||||||||
| Dosage Forms | ||||||||||||||||||||||||||
|
|
|
||||||||||||||||||||||||
| Brand Names | ||||||||||||||||||||||||||
| Other immune globulin intravenous brands include: Alyglo, Asceniv, Bivigam, Carimune NF, Flebogamma, Gammaplex, Octagam, Panzyga, Privigen, Yimmugo View more |
N/A |
Other eltrombopag brands include: Alvaiz, Promacta Kit | ||||||||||||||||||||||||
| Half Life Drug half-life is the time required for plasma concentration to reduce to half its original value. | ||||||||||||||||||||||||||
|
576 hours |
816 hours |
35 hours |
||||||||||||||||||||||||
| CSA Schedule 1 View glossary of CSA terms | ||||||||||||||||||||||||||
|
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
||||||||||||||||||||||||
| Pregnancy Category | ||||||||||||||||||||||||||
|
Category C
Risk cannot be ruled out
See the full pregnancy warnings document. |
Category C
Risk cannot be ruled out
See the full pregnancy warnings document. |
Category C
Risk cannot be ruled out
See the full pregnancy warnings document. |
||||||||||||||||||||||||
| Drug Interactions | ||||||||||||||||||||||||||
|
A total of 107 drugs are known to interact with Gammagard S/D:
|
A total of 10 drugs are known to interact with Nplate:
|
A total of 186 drugs are known to interact with Promacta:
|
||||||||||||||||||||||||
| Alcohol/Food/Lifestyle Interactions | ||||||||||||||||||||||||||
|
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
|
||||||||||||||||||||||||
| Disease Interactions | ||||||||||||||||||||||||||
| First Approval Date | ||||||||||||||||||||||||||
|
N/A |
August 22, 2008 |
November 20, 2008 |
||||||||||||||||||||||||
| WADA Class View classifications | ||||||||||||||||||||||||||
|
N/A |
N/A |
N/A |
||||||||||||||||||||||||
| More Information | ||||||||||||||||||||||||||
| Patient Resources | ||||||||||||||||||||||||||
|
N/A |
||||||||||||||||||||||||||
| Professional Resources | ||||||||||||||||||||||||||
| Related Treatment Guide | ||||||||||||||||||||||||||
1 The Controlled Substances Act (CSA) schedule information displayed applies to substances regulated under federal law. There may be variations in CSA schedules between individual states.
See also:
Imbruvica
Imbruvica (ibrutinib) is used to treat chronic lymphocytic leukemia (CLL), small lymphocytic ...
Rituxan
Rituxan is used to treat certain leukemias and lymphomas and some non-cancer conditions, such as ...
Nplate
Nplate is used to prevent bleeding episodes in people with chronic immune thrombocytopenic purpura ...
Kesimpta
Kesimpta is used to treat relapsing forms of multiple sclerosis (MS), including clinically isolated ...
Brukinsa
Brukinsa is used to treat adults with mantle cell lymphoma, Waldenström’s macroglobulinemia, ma ...
Calquence
Calquence (acalabrutinib) is used to treat chronic lymphocytic leukemia (CLL), and mantle cell ...
Venclexta
Venclexta may be used to treat chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma ...
Ibrutinib
Ibrutinib (Imbruvica) is a Bruton's tyrosine kinase inhibitor used for certain blood cancers and ...
Venetoclax
Venetoclax (brand name Venclexta) may be used to treat CLL, SLL, or AML in those aged 75 years or ...
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.